June 21, 2021
Eisai is joining hands with Bristol Myers Squibb for its first antibody drug conjugate (ADC) MORAb-202, with the two companies announcing their exclusive global strategic collaboration deal on June 18 for the drug, which is currently under development for advanced...read more